What question did this study set out to answer?

This study investigates the metabolites of Caralluma tuberculata and their anti-breast cancer activity.

July 4, 2026Scientific ReportsOpen Access

Integrated metabolomic, cytotoxic, and computational investigation of Caralluma tuberculata extract in breast cancer cells

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial explores the anti-breast cancer effects of Caralluma tuberculata extract, suggesting potential therapeutic applications.

This study investigates the metabolites of Caralluma tuberculata and their anti-breast cancer activity.
Utilized high-performance liquid chromatography (HPLC) and LC-ESI-MS/MS for metabolite analysis.
Assessed cytotoxicity using the MTT assay on MDA-MB-231 and MCF-12F breast cells.
Conducted molecular docking for selected metabolites to assess interactions with CPT1A.
The extract reduced the viability of MDA-MB-231 cells by 44% while affecting MCF-12F cells by only 22%.
Metabolomic analysis identified 60 phytochemicals in C. tuberculata, indicating a diverse profile.
Diosmetin and luteolin showed strong binding affinities to CPT1A in molecular docking simulations.

Ali et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark